EYPT241115P17500
- 0.00
- 0.000.00%
EyePoint Pharmaceuticals Newsroom
EyePoint: JPMorgan, Citigroup Among Managers for Offering >EYPT
EyePoint to Use Net Proceeds From Offering to Advance Clinical Development of Duravyu for Wet Age Related Macular Degeneration, Diabetic Macular Edema >EYPT
EyePoint Pharmaceuticals Grants Underwriters Option for Additional 1.9M Shares >EYPT
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18
EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital
EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?
EyePoint Pharmaceuticals Announces $100M Offering of Common Stock
Express News | EyePoint Pharmaceuticals Inc - Commences $100 Million Public Offering
Express News | EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
12 Health Care Stocks Moving In Monday's Intraday Session
Express News | EyePoint Pharmaceuticals Inc : Jefferies Raises Target Price to $27 From $15
JonesTrading Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $45
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Express News | EyePoint Pharmaceuticals Shares up 25% After Co Reports Interim Mid-Stage Data for Experimental Eye Disease Drug
EyePoint's DURAVYU Shows Results for Diabetic Macular Edema, Improving Vision and Anatomy in Early Trial Data
Express News | EyePoint Pharmaceuticals Inc: Favorable Safety Profile Continues With No Duravyu-Related Ocular or Systemic Saes to Date
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $38
Analyst Ratings For EyePoint Pharmaceuticals
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30